+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 46 Pages
  • April 2023
  • GlobalData
  • Nevro Corp
  • ID: 4278827
Nevro Corp (NVRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nevro Corp (Nevro) is a medical device company, which is engaged in developing novel products that advance the quality of life for people suffering from chronic pain in trunks and limbs. The company has developed Nevro Senza spinal cord stimulation (SCS) system, a non-pharmacological neuromodulation platform for the treatment of chronic pain. The Nevro Senza SCS system is commercially available in the US, Europe, and Australia. The company offers products under Senza, Senza II, Senza Omnia and the Nevro logo brands. Nevro is developing HF10 therapy for treatment related to painful diabetic neuropathy and non-surgical refractory back pain. Nevro is headquartered in Redwood City, California, the US.

Nevro Corp Key Recent Developments

  • Apr 19, 2023: Nevro names Kevin Thornal as new chief executive officer and president
  • Oct 10, 2022: Nevro Comments on UnitedHealthcare Medical Coverage Policy Update
  • Oct 04, 2022: Nevro Announces FDA Approval of Costa Rica Manufacturing Operations
  • Sep 01, 2022: Nevro announces multiple positive coverage updates for the treatment of painful diabetic neuropathy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Nevro Corp - Key Facts
  • Nevro Corp - Key Employees
  • Nevro Corp - Key Employee Biographies
  • Nevro Corp - Major Products and Services
  • Nevro Corp - History
  • Nevro Corp - Company Statement
  • Nevro Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Nevro Corp - Business Description
  • Geographical Segment: International
  • Target Markets
  • Performance
  • Geographical Segment: The US
  • Performance
  • R&D Overview
  • Nevro Corp - Corporate Strategy
  • Nevro Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Nevro Corp - Strengths
  • Nevro Corp - Weaknesses
  • Nevro Corp - Opportunities
  • Nevro Corp - Threats
  • Nevro Corp - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Nevro Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Nevro Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Nevro Corp, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 19, 2023: Nevro names Kevin Thornal as new chief executive officer and president
  • Oct 10, 2022: Nevro Comments on UnitedHealthcare Medical Coverage Policy Update
  • Oct 04, 2022: Nevro Announces FDA Approval of Costa Rica Manufacturing Operations
  • Sep 01, 2022: Nevro announces multiple positive coverage updates for the treatment of painful diabetic neuropathy
  • Aug 01, 2022: Nevro and Boston Scientific announce the settlement of their ongoing intellectual property litigations
  • Apr 06, 2022: Nevro to Report First Quarter 2022 Financial Results
  • Mar 07, 2022: Nevro announces positive Medicare coverage update from Noridian for the treatment of painful diabetic neuropathy
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Nevro Corp, Key Facts
  • Nevro Corp, Key Employees
  • Nevro Corp, Key Employee Biographies
  • Nevro Corp, Major Products and Services
  • Nevro Corp, History
  • Nevro Corp, Subsidiaries
  • Nevro Corp, Key Competitors
  • Nevro Corp, Ratios based on current share price
  • Nevro Corp, Annual Ratios
  • Nevro Corp, Interim Ratios
  • Nevro Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Nevro Corp, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Nevro Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Nevro Corp, Performance Chart (2018 - 2022)
  • Nevro Corp, Ratio Charts
  • Nevro Corp, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Nevro Corp, Medical Equipment, Deals by Type, 2017 to YTD 2023

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Stimwave Technologies Inc
  • Medtronic Plc
  • Boston Scientific Corp
  • Saluda Medical Pty Ltd
  • NeuSpera Medical Inc
  • Abbott Laboratories